KOSDAQIT & Software127120

JS Link

₩15,420▼ 6.03%2026-11-18 close
Market Cap
₩577B
Turnover
₩4.2B
Volume
280K
Shares out.
37.4M
PER
—
PBR
4.5×
EPS
-₩346
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Deficits persist as JS Link moves into permanent magnets

JS Link has recorded operating losses for five straight quarters from Q3 2025 through Q3 2026, and its permanent-magnet business has yet to prove mass production and revenue, which makes both the key watch points.

  1. 1

    Sales rose 21.4% to KRW 19.3 billion in 2025, yet the operating loss widened to KRW 12.5 billion.

  2. 2

    In Q3 2026, sales were KRW 4.79 billion and the operating loss was KRW 5.18 billion, a wider deficit than a year earlier.

  3. 3

    In Q2 2026, net income attributable to controlling shareholders was KRW 8.01 billion despite a KRW 4.16 billion operating loss, a gap that points to non-operating items.

  4. 4

    Press reports say the permanent-magnet segment recorded no sales in Q1 2026, so the revenue base remains thin relative to expansion.

  5. 5

    A Malaysian subsidiary and a Turkish partnership anchor the supply-chain strategy, but convertible bond conversion could sharply increase the share count and add dilution pressure.

02

Business structure

JS Link built its business on genomic analysis and, in August 2024, added permanent-magnet production and sales and rare-earth magnet recycling to its articles of incorporation. It changed its name from DNA Link in March 2025. The business has two pillars.

Genomic analysis relies on government projects, and in May 2025 the company said it had won work worth about KRW 5.5 billion from the Ministry of Science and ICT and about KRW 4.7 billion from the Korea Disease Control and Prevention Agency.

On May 13, 2026 it signed a single-sale supply contract worth roughly KRW 2.48 billion with the National Institute of Health, running through December 11, 2026. The magnet business is at the pilot-production stage at a 1,000-ton-per-year plant in Yesan, Chungnam.

In March 2026 the company disclosed a KRW 50 billion capital injection into a new Malaysian subsidiary, JS LINK MAGNETICS MALAYSIA, which it will own 100%. Press reports say the magnet segment recorded no sales in Q1 2026 and an operating loss of about KRW 2.05 billion.

The company says customer inquiries have come from domestic EV, auto-parts and appliance makers, as well as global technology firms, but these remain at the inquiry stage. The size of government-project revenue and the timing of magnet sales will determine the future business mix.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.2B-₩3.9B−74.8%
2025Q4₩8.9B-₩1.4B−16.3%
2026Q1₩2.4B-₩4.9B−203.4%
2026Q2₩6.3B-₩4.2B−66.0%
2026Q3₩4.8B-₩5.2B−108.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩17B-₩5.1B-₩7.8B−30.3%−27.9%56.0%
2023₩21.9B-₩4.3B-₩5.6B−19.8%−21.3%47.5%
2024₩15.9B-₩9.1B-₩10.8B−57.3%−43.2%117.3%
2025₩19.3B-₩12.5B-₩16.4B−64.6%−24.0%79.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a disclosed basis, annual sales went from KRW 17 billion in 2022 to KRW 21.9 billion in 2023 (up 29.3%), fell to KRW 15.9 billion in 2024 (down 27.5%), and recovered to KRW 19.3 billion in 2025 (up 21.4%). 2023 was the largest year in the period and 2024 the smallest.

The company attributed the 2025 sales increase to genomic-analysis government projects. The same filing cited higher facility and headcount investment for new-business entry as the reason losses widened.

Operating losses were KRW 5.15 billion in 2022, KRW 4.34 billion in 2023, KRW 9.11 billion in 2024 and KRW 12.5 billion in 2025, a loss in each of the four years from 2022 to 2025. The operating margin improved from -30.3% in 2022 to -19.8% in 2023, then fell to -57.3% in 2024 and -64.6% in 2025.

Losses grew in 2025 even as sales rose, suggesting new-business investment costs rose faster than revenue. Net loss attributable to controlling shareholders went from KRW 7.78 billion in 2022 to KRW 16.4 billion in 2025.

Total net loss, including non-controlling interests, was KRW 8.08 billion in 2022, a different figure from the controlling-shareholder number. Operating cash flow swung from a KRW 910 million inflow in 2022 to outflows of KRW 5.03 billion in 2023, KRW 6.78 billion in 2024 and KRW 9.39 billion in 2025.

The debt-to-equity ratio rose to 117.3% in 2024 and fell to 79.4% in 2025, with year-end 2025 total equity of KRW 68.6 billion, all attributable to controlling shareholders, and total liabilities of KRW 54.4 billion.

Quarterly, operating losses were KRW 3.86 billion in Q3 2025, KRW 1.44 billion in Q4 2025, KRW 4.92 billion in Q1 2026, KRW 4.16 billion in Q2 2026 and KRW 5.18 billion in Q3 2026.

Net income attributable to controlling shareholders was KRW 8.01 billion in Q2 2026, a turn to profit, and a loss of KRW 9.74 billion in Q3 2026, a turn back to loss. The four quarters from Q4 2025 to Q3 2026 total KRW 11.2 billion in losses attributable to controlling shareholders.

05

Industry analysis

JS Link's magnet business targets demand from EVs, wind power and home appliances. Press reports say Turkey has domestic rare-earth resources and auto and wind-power industries, so a local production base could extend supply to nearby European markets.

On the demand side, the company argues that U.S. defense-procurement restrictions on Chinese-made rare-earth magnets from 2026 favor firms with U.S.-based magnet capacity.

A 2025 press report cited SK Securities' view that the company could benefit as magnet prices rise and supply chains are reorganized amid U.S.-China tensions. Technical hurdles remain.

The flagship N52 grade has strong magnetism but weak heat resistance, so the company must prove stable output in heat-resistant grades such as 45UH, 50H and 38SH. On raw materials, the strategic partnership with Australia's Lynas Rare Earths is presented as a way to reduce dependence on China.

Compared with domestic listed IT and software peers, which mostly earn service-based revenue, JS Link is moving toward a manufacturing model with heavier capital spending.

06

Outlook

The concrete milestones JS Link has described include staged capital injections into its Malaysian subsidiary, and a planned 3,000-ton-per-year plant in Kuantan, Malaysia, co-developed with Lynas.

For Turkey, the plan starts with a 1,000-ton-per-year integrated line built on an initial finishing facility, with capacity under review of up to 3,000 tons. Reports from November 2026 describe a rare-earth MOU signed around the Korea-Turkey summit.

A 2025 report said the Georgia, U.S. plant targeted operation by late 2027. In 2025 the company expected magnet revenue recognition as early as Q4 2025 after pilot production and mass-production preparations, but press reports say the magnet segment recorded no sales in Q1 2026.

In July 2026 the company announced a strategic partnership with Lynas and an update on 45UH performance verification. On the genomic side, the Korea Disease Control and Prevention Agency contract runs through December 11, 2026, so whether it is completed and recognized as revenue is the nearest checkpoint. In 2025 the company planned a total capacity of 9,000 tons across Yesan, the U.S. and Malaysia.

07

Valuation

PER
—
PBR
4.5×
ROE
-11.9%
EPS
-₩346
BPS
₩4,088
Dividend per share
₩0

JS Link's share price appears to price in expectations for the permanent-magnet business more than current earnings. Because losses attributable to controlling shareholders over the four quarters from Q4 2025 to Q3 2026 total KRW 11.2 billion, the earnings-based PER cannot be calculated.

On a book-value basis the stock sits in a high-premium range relative to net asset value per share. The company pays no dividend, so a dividend-based valuation comparison does not apply.

Press reports noted that the share price rose sharply over the past year while earnings lagged, widening the gap between results and the stock.

The key valuation variables are the timing and scale of magnet revenue, and the share count that could rise through convertible bonds and rights offerings should be reflected in any per-share value estimate.

The stock has previously been designated under KRX market-warning measures, so price volatility is itself a cited market risk.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Supply-chain realignment demand

The company stresses that U.S. defense-procurement limits on Chinese rare-earth magnets from 2026 raise the value of non-Chinese production. A 2025 press report cited SK Securities' view that magnet price increases and supply-chain reorganization could benefit the company. If the trend persists, the Malaysian and Turkish sites could address that demand.

Public genomic-project contract base

In 2025 the company said it had won government work including about KRW 5.5 billion from the Ministry of Science and ICT and about KRW 4.7 billion from the Korea Disease Control and Prevention Agency. In May 2026 it signed a supply contract worth about KRW 2.48 billion with the National Institute of Health. This legacy business supports revenue while magnet sales are still absent.

Overseas partnerships and anchor-shareholder funding

The company formed a strategic partnership with Lynas and, in November 2026, a rare-earth MOU was signed in Turkey on the sidelines of the Korea-Turkey summit. Press coverage notes that the major shareholder group injected about KRW 62 billion through five private rights offerings.

The KRW 50 billion Malaysian subsidiary capital decision is a disclosed signal of commitment to production sites.

09

Bear factors

Losses persist before magnet revenue

Disclosed operating losses widened to KRW 12.5 billion in 2025, and the company has posted operating losses for five straight quarters from Q3 2025 through Q3 2026. Press reports say the magnet segment booked a KRW 2.05 billion operating loss in Q1 2026 with no sales. Operating cash outflow grew to KRW 9.39 billion in 2025.

Dilution from convertible bonds and rights offerings

Press reports calculate that converting all outstanding convertible bonds would equal about 13.78% of the pre-existing share count, and about 18.6% including the Lynas rights-offering shares. Several low-conversion-price bonds are already eligible for conversion. The largest shareholder's stake could fall below 25% on the same arithmetic.

Mass-production proof and technical hurdles

Press coverage says the Yesan plant has only partly completed N52-grade sample production and quality checks, so mass-production capacity is not yet proven. N52 has weak heat resistance, and the company has tied U.S. cooperation to quality verification of heat-resistant grades such as 45UH. Revenue-recognition timing has been pushed back before.

10

Risk factors

Dilution and governance

Continued convertible bonds and private rights offerings keep diluting existing holders. A 2025 press report raised questions over personnel moves from a failed rare-earth project at another company, which JS Link denied. Two new outside directors were elected at the March 2026 shareholder meeting, changing the board.

Delay in revenue conversion

The company expected magnet revenue recognition as early as Q4 2025, but press reports say the segment recorded no sales in Q1 2026. Start-up timing for the Malaysian and U.S. plants is still moving with schedules. The longer plants take to run, the longer capital and losses accumulate first.

Trading restrictions and volatility

KRX designated the stock as a caution stock in February 2026, then as a warning stock on February 19, 2026, removed the warning on March 6, and re-designated it as a caution stock that day. A warning designation was applied again on July 1, 2026, and further sharp gains can trigger a temporary trading halt.

Because JS Link listed under the technology-special track, it is also exempt from some listing-maintenance rules, which is cited as a variable.

11

What to watch next

  1. December 11, 2026

    The supply contract with the National Institute of Health ends. Completion and revenue recognition are the near-term checkpoints for the genomic business.

  2. Around March 31, 2027

    The deadline for the 2026 annual report. Full-year sales, operating loss and whether the magnet segment booked any revenue will be confirmed in the regular filing.

  3. Around May 15, 2027

    The deadline for the Q1 2027 quarterly report. Whether magnet revenue first appears and whether quarterly operating losses narrow are the checkpoints.

  4. Late 2027

    The target start-up period for the Columbus, Georgia plant, as set out in a 2025 press report. Whether the schedule holds will show how the U.S. production strategy is progressing.

12

Overall view

JS Link runs two businesses: government-funded genomic analysis and a new permanent-magnet venture. Disclosed 2025 sales rose to KRW 19.3 billion, yet the operating loss widened to KRW 12.5 billion, and operating losses have run for five straight quarters through Q3 2026.

Net income attributable to controlling shareholders turned positive in Q2 2026, but the gap from that quarter's operating loss points to non-operating factors.

Strengths include demand for non-Chinese rare-earth supply, the Malaysian and Turkish production sites, the Lynas partnership and the public genomic contract base.

Weaknesses include the lack of confirmed magnet revenue, dilution from convertible bonds, unproven mass production and the record of KRX trading designations. Because the gap between business expectations and reported results is wide, market views of the share price can diverge.

The next checkpoints are the end of the supply contract on December 11, 2026 and whether the 2026 annual report shows magnet-segment revenue. Watching whether magnet sales arrive on schedule and how the dilution share count evolves is central to this stock.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. eduinfom.com
  2. greened.kr
  3. view.asiae.co.kr
  4. digitaltoday.co.kr
  5. m.news.nate.com
  6. ibtomato.com
  7. etoday.co.kr
  8. dealsite.co.kr
  9. fnnews.com
  10. news.nate.com
  11. m.news.nate.com
  12. topstarnews.net
  13. m.news.nate.com
  14. topstarnews.net
  15. topstarnews.net
  16. topstarnews.net
  17. jslink.co.kr
  18. topstarnews.net

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis